Overview

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its placebo). We measured the abdominal fat content and blood sugar levels of participants before and after 40 weeks of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Treatments:
Hormones
Pioglitazone